1432913-36-4
1432913-36-4
Chemical Structure
GX-674
- CAS No.: 1432913-36-4
- Formula:C21H13ClF2N6O3S2
- Molecular Weight:534.95
IUPAC Name: 4-(2-(2-amino-1H-benzo[d]imidazol-6-yl)-4-chlorophenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide
InChIKey: NLTQZTZBFNPMDH-UHFFFAOYSA-N
SMILES: O=S(C1=CC(F)=C(OC2=CC=C(Cl)C=C2C3=CC=C4N=C(N)NC4=C3)C=C1F)(NC5=NC=NS5)=O
Biological Activity: GX-674 is a selective NaV1.7 inhibitor with an IC50 of 0.1 nM against hNaV1.7. GX-674 can be used for research on pain, neuropathic pain, and arrhythmia[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GX-674 | 98.45% | GX-674 is a selective NaV1.7 inhibitor with an IC50 of 0.1 nM against hNaV1.7. GX-674 can be used for research on pain, neuropathic pain, and arrhythmia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Goodchild SJ, et al. Molecular Pharmacology of Selective Na1.6 and Dual Na1.6/Na1.2 Channel Inhibitors that Suppress Excitatory Neuronal Activity Ex Vivo. ACS chemical neuroscience. 2024 Mar 20;15(6):1169-1184. [Content Brief]
- [2]. Bankar G, et al. Selective Na1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic Pain. Cell reports. 2018 Sep 18;24(12):3133-3145. [Content Brief]
- [3]. Payandeh J, et al. Selective Ligands and Drug Discovery Targeting the Voltage-Gated Sodium Channel Nav1.7. Handbook of experimental pharmacology. 2018;246:271-306. [Content Brief]
- [4]. Pukkanasut P, et al. Therapeutic targeting of voltage-gated sodium channel Na1.7 for cancer metastasis. Frontiers in pharmacology. 2024;15:1416705.
- [5]. Clark CJ. Sodium Current Composition and Remodeling in Murine Cardiomyocytes (Doctoral dissertation.
- [6]. François-Moutal L. Inhibition of the Ubc9 E2 SUMO conjugating enzyme–CRMP2 interaction decreases NaV1. 7 currents and reverses experimental neuropathic pain. Pain. 2018 Oct;159(10):2115.
- [7]. Nguyen PT, et al. Towards Structure-Guided Development of Pain Therapeutics Targeting Voltage-Gated Sodium Channels. Frontiers in pharmacology. 2022;13:842032.
